1. Stocks
    2. /
  2. Immutep Limited (ASX: IMM)
    3. /

Immutep Limited (ASX: IMM) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Immutep Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Immutep Limited (ASX: IMM)
    Latest News

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Why has this ASX healthcare share exploded 50% in two days?

    | Monica O'Shea

    The biotech company is riding high on the back of promising clinical trial data.

    Read more »

    Health workers shake hands and congratulate each other on good news.
    Healthcare Shares

    2 ASX healthcare shares smashing the All Ords today

    | James Mickleboro

    These healthcare shares are smashing the All Ords today...

    Read more »

    A CSL scientist looking through a telescope in a lab
    Healthcare Shares

    What's the outlook for Immutep shares in FY23?

    | Zach Bristow

    The biotech company continues its clinical trial momentum.

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Healthcare Shares

    What's the outlook for ASX biotech shares in FY23?

    | Zach Bristow

    ASX biotech shares could be changing course in FY23.

    Read more »

    A sad looking scientist sitting and upset about a share price fall.
    Healthcare Shares

    Why did the Immutep share price plummet 31% last month?

    | Brooke Cooper

    June was a rough one for this ASX biotechnology stock.

    Read more »

    Two staff in a medical research laboratory wearing masks and caps work on their tests, representing the performance of ASX healthcare shares in FY22
    Healthcare Shares

    Here's how ASX healthcare shares performed in FY22

    | Zach Bristow

    ASX healthcare shares took a massive plunge from the restart of trade in January.

    Read more »

    Two researchers discussing results of a study with each other.
    Healthcare Shares

    Here's how ASX 200 healthcare shares performed in June

    | Zach Bristow

    Healthcare shares were a tad ill in June.

    Read more »

    A businessman presents a company annual report in front of a group seated at a table
    Healthcare Shares

    Own Immutep shares? Here are 3 takeaways from the company's investor update

    | Zach Bristow

    Investors were mute to the update.

    Read more »

    A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
    Healthcare Shares

    What's driving the Immutep share price in June?

    | Zach Bristow

    Can the ASX healthcare share maintain its momentum this month?

    Read more »

    Rocket powering up and symbolising a rising share price.
    Healthcare Shares

    Why has the Immutep share price rocketed 24% in a month?

    | Brooke Cooper

    Here's what's been going right for the biotech stock lately.

    Read more »

    Two happy scientists analysing test results in a lab
    Healthcare Shares

    10-baggers? Expert names 2 super-cheap biotech ASX shares

    | Tony Yoo

    Biotech and health tech stocks have suffered greatly in recent months. But one fund manager is sticking by 2 particular…

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    | Bernd Struben

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    Frequently Asked Questions

    No, Immutep does not pay dividends at this time.

    Immutep Ltd listed on the ASX on 23 June 1988.

    IMM ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Immutep Limited

    Immutep Ltd (ASX: IMM) is a biotechnology company developing immunotherapy products for cancer and autoimmune diseases. The company describes itself as a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Immutep's LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune diseases. Immutep currently has three clinical-stage candidates and two earlier-stage candidates.

    Profile

    since

    Note